FDA Grants Orphan Drug Status to Adcentrx’s ADRX-0405 for Gastric Cancer
Adcentrx Therapeutics, a clinical-stage biotech company specializing in Antibody-Drug Conjugate (ADC) therapies, announced that the U.S. Food and Drug Administration (FDA) has granted…
Read More...
Read More...
